Clinical

Patient-reported outcome measures may have a small impact on predicting which patients with cirrhosis will be readmitted to the hospital.

Results of a cross-sectional study point to a potential link between iron intake and migraine that may be dependent on age.

The latest news in rheumatology includes the need for robust vaccinations in juvenile idiopathic arthritis; new findings about rheumatoid arthritis (RA) and type 2 diabetes; and quality of life in systemic lupus erythematosus.

In an interim analyses of the phase 3 SEQUOIA trial, zanubrutinib had superior progression-free survival compared with bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).

One diagnosis challenge is that there is no specific biomarker, either for autoimmune hepatitis (AIH) or metabolic-associated fatty liver disease (MAFLD), either alone or if they exist concurrently.

William "Andy" Nish, MD, an allergist and immunologist at Northeast Georgia Physicians Group, discusses the factors that influence whether patients with asthma should be prescribed a biologic therapy.

A newly released internal CDC report shows the agency's communication struggles and its challenges in combatting the virulent delta variant, acknowledges the need for universal masking, and illustrates the effectiveness of vaccines in preventing more severe illness and death in those who are inoculated.

A new CMS rule increases reimbursement for providers; coffee is linked to decreased risk of arrhythmia; the Johnson & Johnson COVID-19 vaccine’s shelf life is extended.

A new report is issuing a call to action to develop a global strategy to address the growing issue of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician.

Review findings outline the gut microbiome's potential impact on immunotherapy responses.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

In the June Matters in Managed Care webinar, experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed discussed how they are working together to address some of the state’s unique primary care needs.

About 4 in 10 patients with chronic kidney disease will have “early rapid decline,” a trajectory more likely if the patient also has diabetes.

Clinicians should avoid prescribing acid-suppression medications in general, and especially proton-pump inhibitors, to patients with Clostridioides difficile infection, according to the study.

While polypharmacy, along with hospital length of stay and other factors, was linked to a higher risk of 30-day hospital readmission, the type of medication mattered as well.

Patients may find a placebo effect beneficial, but it causes issues in a clinical trial and makes it difficult to understand the efficacy of a pharmacological agent, said Ron Eccles, BSc, PhD, DSc, emeritus professor at Cardiff University.

Viral infections can induce asthma exacerbations, but a report finds the inflammation itself can also have an impact on the infection.

The issue of reactivating hepatitis B and other chronic viruses such as herpes zoster after treatment for myeloproliferative neoplasms (MPN) is an emerging issue in hematologic malignancies, due to the power of newer therapies.

Many respiratory viruses demonstrated atypical activity levels as compared with previous rates of activity during pre-pandemic seasonality, the CDC said this week.

Compared with chemotherapy, patients receiving avelumab or another immunotherapy had higher response rates and higher rates of survival in locally advanced Merkel cell carcinoma (laMCC) and metastatic Merkel cell carcinoma (mMCC).

Dynamic measurable residual disease (MRD) can be used to optimize postremission treatment for young patients with acute myeloid leukemia (AML).

The gold standard for diagnosing liver disease is a liver biopsy, but researchers are seeking a simpler way to identify those at risk, given the silent nature of early disease and rising incidence around the globe.

Across 19 patients, 73% developed grade 3 or 4 neutropenia, significantly higher than the incidence observed in the phase 3 trial examining the combination for chronic lymphocytic leukemia (CLL).